Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Journal of Hepatology

Volumn 66, Issue 5, 2017, Pages 1022-1030

  Karlas, Thomas ^a   Petroff, David ^b   Sasso, Magali ^c   Fan, Jian Gao ^d   Mi, Yu Qiang ^e   de Lédinghen, Victor ^f   Kumar, Manoj ^g   Lupsor Platon, Monica ^h   Han, Kwang Hyub ⁱ   Cardoso, Ana C ^j   Ferraioli, Giovanna ^k   Chan, Wah Kheong ^l   Wong, Vincent Wai Sun ^m   Myers, Robert P ⁿ   Chayama, Kazuaki ^o   Friedrich Rust, Mireen ^p   Beaugrand, Michel ^q   Shen, Feng ^d   Hiriart, Jean Baptiste ^f   Sarin, Shiv K ^g   Badea, Radu ^h   Jung, Kyu Sik ⁱ   Marcellin, Patrick ^j   Filice, Carlo ^k   Mahadeva, Sanjiv ^l   Wong, Grace Lai Hung ^m   Crotty, Pam ⁿ   Masaki, Keiichi ^o   Bojunga, Joerg ^p   Bedossa, Pierre ^r   Keim, Volker ^a   Wiegand, Johannes ^a   more..

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c R and D Department   (France)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e TIANJIN SECOND PEOPLE S HOSPITAL   (China)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

^h IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

ⁱ Yonsei University College of Medicine   (South Korea)

^j CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^k UNIVERSITY OF PAVIA   (Italy)

^l UNIVERSITY OF MALAYA   (Malaysia)

^m CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁿ UNIVERSITY OF CALGARY   (Canada)

^o HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^p UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^q HÔPITAL JEAN VERDIER   (France)

^r UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Controlled attenuation parameter (CAP); Liver steatosis; Transient elastography (TE)

Indexed keywords

ADULT; ARTICLE; BODY MASS; CONTROLLED ATTENUATION PARAMETER; DATA ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; PATIENT CODING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY; DIAGNOSTIC IMAGING; ECHOGRAPHY; META ANALYSIS (TOPIC); PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; BODY MASS INDEX; FATTY LIVER; FEMALE; HEPATOCYTES; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; ROC CURVE; ULTRASONOGRAPHY;

EID: 85010832078     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.12.022     Document Type: Article

References (59)

1. [1] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
2. [2] AASLD/IDSA, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
3. [3] O'Shea, R.S., Dasarathy, S., McCullough, A.J., Alcoholic liver disease. Am J Gastroenterol 105 (2009), 14–32.
4. [4] Terrault, N.A., Bzowej, N.H., Chang, K., Hwang, J.P., Jonas, M.M., Murad, M.H., AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
5. [5] Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654, e9.
6. [6] Castera, L., Hezode, C., Roudot-Thoraval, F., Bastie, A., Zafrani, E.S., Pawlotsky, J.M., et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52 (2003), 288–292.
7. [7] Lok, A.S., Everhart, J.E., Chung, R.T., Padmanabhan, L., Greenson, J.K., Shiffman, M.L., et al. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol 5 (2007), 245–254.
8. [8] Liang, C., Liu, C., Chung, C., Lin, C., Su, T., Yang, H., et al. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy. J Infect Dis 211 (2015), 1429–1436.
9. [9] Soresi, M., Tripi, S., Franco, V., Giannitrapani, L., Alessandri, A., Rappa, F., et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 26 (2006), 1119–1125.
10. [10] Dyal, H.K., Aguilar, M., Bhuket, T., Liu, B., Holt, E.W., Torres, S., et al. Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients: a systematic review. Dig Dis Sci 60 (2015), 2813–2824.
11. [11] Berzigotti, A., Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: Controlled attenuation parameter for steatosis. J Hepatol 60 (2014), 910–912.
12. [12] Hudacko, R., Theise, N., Liver biopsies in chronic viral hepatitis: beyond grading and staging. Arch Pathol Lab Med 135 (2011), 1320–1328.
13. [13] Brown, G.T., Kleiner, D.E., Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 65 (2016), 1080–1086.
14. [14] Bedossa, P., Carrat, F., Liver biopsy: The best, not the gold standard. J Hepatol 50 (2009), 1–3.
15. [15] Aldoheyan, T., Hassanain, M., Al-Mulhim, A., Al-Sabhan, A., Al-Amro, S., Bamehriz, F., et al. The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc, 2016, 10.1007/s00464-016-5082-8.
16. [16] Raptis, D.A., Fischer, M.A., Graf, R., Nanz, D., Weber, A., Moritz, W., et al. MRI: The new reference standard in quantifying hepatic steatosis?. Gut 61 (2011), 117–127.
17. [17] Wu, C., Ho, M., Jeng, Y., Hsu, C., Liang, P., Hu, R., et al. Quantification of hepatic steatosis: A comparison of the accuracy among multiple magnetic resonance techniques. J Gastroenterol Hepatol 29 (2014), 807–813.
18. [18] Karlas, T., Petroff, D., Is magnetic resonance imaging really more accurate for classifying steatosis than controlled attenuation parameter?. Gastroenterology 151 (2016), 374–375.
19. [19] EASL–EASD–EASO, EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1388–1402.
20. [20] Wong, G.L., Wong, V.W., Fat and fiber: how the controlled attenuation parameter complements noninvasive assessment of liver fibrosis. Dig Dis Sci 60 (2015), 9–12.
21. [21] Sasso, M., Miette, V., Sandrin, L., Beaugrand, M., The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan®. Clin Res Hepatol Gastroenterol 36 (2012), 13–20.
22. [22] Sasso, M., Beaugrand, M., de Ledinghen, V., Douvin, C., Marcellin, P., Poupon, R., et al. Controlled Attenuation Parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 36 (2010), 1825–1835.
23. [23] de Lédinghen, V., Vergniol, J., Capdepont, M., Chermak, F., Hiriart, J., Cassinotto, C., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. J Hepatol 60 (2014), 1026–1031.
24. [24] Shi, K., Tang, J., Zhu, X., Ying, L., Li, D., Gao, J., et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 29 (2014), 1149–1158.
25. [25] Wang, Y., Fan, Q., Wang, T., Wen, J., Wang, H., Zhang, T., Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. Int J Clin Exp Med 8 (2015), 17654–17663.
26. [26] Lambert, P.C., Sutton, A.J., Abrams, K.R., Jones, D.R., A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 55 (2002), 86–94.
27. [27] Stewart, G.B., Altman, D.G., Askie, L.M., Duley, L., Simmonds, M.C., Stewart, L.A., et al. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. PLoS One, 7, 2012, e46042.
28. [28] Boursier, J., Zarski, J., de Ledinghen, V., Rousselet, M., Sturm, N., Lebail, B., et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 57 (2013), 1182–1191.
29. [29] Shen, F., Zheng, R.D., Mi, Y.Q., Wang, X.Y., Pan, Q., Chen, G.Y., et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. WJG, 20, 2014, 4702.
30. [30] Pais, R., Charlotte, F., Fedchuk, L., Bedossa, P., Lebray, P., Poynard, T., et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 59 (2013), 550–556.
31. [31] Bedossa, P., The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20 (1994), 15–20.
32. [32] Kleiner, D.E., Brunt, E.M., van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
33. [33] Ishak, K., Baptista, A., Bianchi, L., Callea, F., de Groote, J., Gudat, F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995), 696–699.
34. [34] R Core Team. R: A language and environment for statistical computing. 2014, R Foundation for Statistical Computing, Vienna, Austria.
35. [35] Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J., et al. PROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics, 12, 2011, 77.
36. [36] Karlas, T., Petroff, D., Garnov, N., Böhm, S., Tenckhoff, H., Wittekind, C., et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One, 9, 2014, e91987.
37. [37] Venables, W.N., Ripley, B.D., Modern applied statistics with S. 4th ed., 2002, Springer, New York.
38. [38] Bates, D., Mächler, M., Bolker, B., Walker, S., Fitting linear mixed-effects models using lme4. arXiv:1406.5823v1, 2014.
39. [39] Lupșor-Platon, M., Feier, D., Stefănescu, H., Tamas, A., Botan, E., Sparchez, Z., et al. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: A prospective study. J Gastrointestin Liver Dis 24 (2015), 35–42.
40. [40] Kwok, R., Choi, K.C., Wong, G.L., Zhang, Y., Chan, H.L., Luk, A.O., et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study. Gut 65 (2016), 1359–1368.
41. [41] Cardoso, A., Beaugrand, M., de Ledinghen, V., Douvin, C., Poupon, R., Trinchet, J., et al. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. Ann Hepatol 14 (2015), 826–836.
42. [42] Jung, K.S., Kim, B.K., Kim, S.U., Chon, Y.E., Cheon, K.H., Kim, S.B., et al. Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. PLoS One, 9, 2014, e98689.
43. [43] Ferraioli, G., Tinelli, C., Lissandrin, R., Zicchetti, M., Dal Bello, B., Filice, G., et al. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World J Gastroenterol 20 (2014), 6626–6631.
44. [44] Chon, Y.E., Jung, K.S., Kim, S.U., Park, J.Y., Park, Y.N., Kim, D.Y., et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: A prospective study of a native Korean population. Liver Int 34 (2014), 102–109.
45. [45] Chan, W., Nik Mustapha, N.R., Mahadeva, S., Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 29 (2014), 1470–1476.
46. [46] Masaki, K., Takaki, S., Hyogo, H., Kobayashi, T., Fukuhara, T., Naeshiro, N., et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res 43 (2013), 1182–1189.
47. [47] Kumar, M., Rastogi, A., Singh, T., Behari, C., Gupta, E., Garg, H., et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: Does etiology affect performance?. J Gastroenterol Hepatol 28 (2013), 1194–1201.
48. [48] Myers, R.P., Pollett, A., Kirsch, R., Pomier-Layrargues, G., Beaton, M., Levstik, M., et al. Controlled Attenuation Parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 32 (2012), 902–910.
49. [49] Friedrich-Rust, M., Romen, D., Vermehren, J., Kriener, S., Sadet, D., Herrmann, E., et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 81 (2012), e325–e331.
50. [50] Lédinghen, V., Vergniol, J., Foucher, J., Merrouche, W., Bail, B., Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 32 (2012), 911–918.
51. [51] Sasso, M., Tengher-Barna, I., Ziol, M., Miette, V., Fournier, C., Sandrin, L., et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: Validation in chronic hepatitis C. J Viral Hepat 19 (2012), 244–253.
52. [52] Mi, Y., Shi, Q., Xu, L., Shi, R., Liu, Y., Li, P., et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B. Dig Dis Sci 60 (2015), 243–251.
53. [53] Shen, F., Zheng, R., Shi, J., Mi, Y., Chen, G., Hu, X., et al. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. Liver Int 35 (2015), 2392–2400.
54. [54] Haring, R., Wallaschofski, H., Nauck, M., Dörr, M., Baumeister, S.E., Völzke, H., Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 50 (2009), 1403–1411.
55. [55] Schwenzer, N.F., Springer, F., Schraml, C., Stefan, N., Machann, J., Schick, F., Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51 (2009), 433–445.
56. [56] European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63 (2015), 237–264.
57. [57] Imajo, K., Kessoku, T., Honda, Y., Tomeno, W., Ogawa, Y., Mawatari, H., et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150 (2016), 626–637, e7.
58. [58] Petta, S., Di Marco, V., Camma, C., Butera, G., Cabibi, D., Craxi, A., Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 33 (2011), 1350–1360.
59. [59] Sasso, M., Audiere, S., Kemgang, A., Gaouar, F., Corpechot, C., Chazouilleres, O., et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnostic accuracy. Ultrasound Med Biol 42 (2016), 92–103.